Supplementary Data from Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Materials
Authors: Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362432339